CYCLOSPORIN A IN RHEUMATOID ARTHRITIS

环孢素A(CsA)每日口服对慢性粒细胞白血病的疗效和毒性 活动期类风湿性关节炎患者正在接受一项 低剂量(1 mg/kg/天)与高剂量(1 mg/kg/d)的6个月双盲研究 CsA(10 mg/kg/d)。每周都会对毒性进行监测 先是2个月，然后每隔2周直到6个月。疾病 活动每两个月进行一次评估。不这样做的患者 在6岁时疾病活跃度至少提高40% 从研究中去掉了几个月，而那些得分在40%或以上的人 在额外的6个月服药期间继续有更大的反应 心理治疗。环孢素A对不同T测定指标的影响 外周血和滑膜中的淋巴细胞功能 在所有患者中都进行了研究。

The efficacy and toxicity of daily, oral cyclosporin A (CSA) in patients with active rheumatoid arthritis is being evaluated in a 6 month double-blind study of low dose (lmg/kg/day) versus high dose (10mg/kg/day) CSA. Toxicity is monitored weekly for the first 2 months and then every 2 weeks until 6 months. Disease activity is assessed on a bi-monthly basis. Patients who do not develop at least a 40% improvement in disease activity at 6 months are dropped from the study, while those with a 40% or greater response continue for an additional 6 months of drug therapy. The effects of CSA on various measures of T lymphocyte function in peripheral blood and within the synovium is studied in all patients.